Viking Therapeutics (VKTX) moved back into focus after its latest earnings release, as the biotech reported a third quarter net loss of US$183.19 million and wider losses over the first nine months of 2026.
That widening loss landed against a weak share price backdrop for Viking Therapeutics, with the stock at US$26.84 and a 90 day share price return down 20.59% and year-to-date share price return down 24.22%, even though the 3 year total shareholder return is up more than 170%.
Scan beyond Viking Therapeutics and compare this earnings-driven pullback with a hand picked set of 19 high quality undiscovered gems that also pair heavy R&D spend with strong underlying fundamentals.
Given Viking Therapeutics now pairs heavier losses with a sharply lower share price, does the balance of risk and potential reward still lean toward buyers, or does it argue for more caution on valuation grounds?
Most Popular Narrative: 79% Undervalued
On the bullish analyst Narrative on Simply Wall St, Viking Therapeutics screens as heavily undervalued, with a Fair Value of $125 against a last close of $26.84. This puts the focus firmly on how much has to go right in the obesity pipeline.
The initiation of two 68 week Phase III SUNRISE trials for oral VK2735, using daily doses across a wide range and targeting both obesity with comorbidities and obesity with type 2 diabetes, gives Viking Therapeutics a path to segment the market by formulation and indication. This can support incremental revenue streams and operating leverage.
See why 4 investors see Viking Therapeutics as 79% undervalued.
Result: Fair Value of $125 (UNDERVALUED)
Still, the bullish Viking Therapeutics story leans heavily on successful VK2735 trials and disciplined cash burn, and setbacks on either front could quickly challenge that 79% undervalued narrative.
Find out about the key risks to this Viking Therapeutics narrative.
Another View: Viking Therapeutics Looks Expensive On Book Value
The bullish fair value of $125 leans on long term obesity optionality. A simpler check using today’s balance sheet points a different way. Viking Therapeutics trades on a P/B of 5.8x compared with 1.8x for the wider US Biotechs group and around 6.8x for close peers. Book-based buyers are therefore paying a rich premium for a business still reporting heavy losses. Does that gap reflect unique pipeline potential, or does it simply leave less room for error if trial or funding news disappoints?
For anyone weighing that question through a multiples lens rather than future cash flows, See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Mixed signals on Viking Therapeutics can pull you in either direction, so move fast, review the key numbers, and weigh the 3 important warning signs against your own tolerance for downside.
Looking for more investment ideas beyond Viking Therapeutics?
Do not stop your research with Viking Therapeutics. Broaden your watchlist with a few focused stock shortlists that line up with the kind of risks you actually want.
- Target strong upside potential while keeping quality in view by scanning a curated pool of 40 high quality undervalued stocks that pair solid fundamentals with compressed valuations.
- Prioritise resilience and aim to sleep better at night by reviewing a 31 resilient stocks with low risk scores that filters for sturdier balance sheets and milder business swings.
- Hunt for potential future leaders early by checking a 10 elite penny stocks with strong financials where financial strength screens out weaker stories and leaves a tighter field of candidates.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com